Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's AWARE-1 study demonstrated positive signal in TNBC

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 16, 2021 11:31am

180 Views

Post# 33559583

RE:ONCY's AWARE-1 study demonstrated positive signal in TNBC

July 15, 2021 -

Immune Checkpoint Inhibitor (pembrolizumab) Plus Chemotherapy (paclitaxel and carboplatin) before surgery and continued as a single agent after surgery showed statistically significant Event-Free Survival (EFS) result versus Neoadjuvant Chemotherapy (paclitaxel and carboplatin) alone in High-Risk Early-Stage TNBC

https://www.biospace.com/article/releases/keytruda-pembrolizumab-plus-chemotherapy-before-surgery-and-continued-as-a-single-agent-after-surgery-showed-statistically-significant-event-free-survival-efs-result-versus-neoadjuvant-chemotherapy-alone-in-high-risk-early-stage-tnbc/

Now think of the increased benefit with the addition of ONCY's oncolytic virus pelareorep to the above referenced combination in TNBC as the combination of paclitaxel/carboplatin with pelareorep has proven safe and effective.

https://pubmed.ncbi.nlm.nih.gov/28289863/

In Aug. 26, 2020 Oncolytics Biotech® Inc. announced the first patient had been dosed in the Company's investigator-sponsored IRENE phase 2 study of pelareorep-anti-PD-1 combination therapy in unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). The study is co-sponsored by Oncolytics, the Rutgers Cancer Institute of New Jersey, and Incyte. Participants in the multi-center study receive pelareorep in combination with Incyte's anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012)

Now think of the increased benefit with the addition of ONCY's oncolytic virus pelareorep to the above referenced combination in TNBC as the combination of paclitaxel/carboplatin with pelareorep has proven safe and effective.

https://pubmed.ncbi.nlm.nih.gov/28289863/

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?